HOME    |    SITEMAP    |    CONTACT    |    

Share  | 
Product Pipeline

Product Pipeline - Overview

Mersana is advancing a pipeline of next-generation drug candidates with the potential to improve patient outcomes in multiple oncology indications. Our approach to developing novel drug candidates begins with identifying a clinical unmet need, and then engineering novel drug conjugates that incorporate our Fleximer® polymer and linker chemistries customized to reach the desired activity profile and to overcome clinical obstacles.

 

This approach is particularly well suited for antibody-drug conjugate (ADC) engineering, successfully exploiting both full-length monoclonal antibodies and antibody fragments. Mersana is developing a portfolio of next-generation ADCs with superior properties not found with current ADC technologies.

Our clinical-stage product candidates reflect the successful application of our unique conjugation system. XMT-1001 is a potentially best-in-class novel "tecan" conjugate that is currently being investigated in a Phase 1b extension trial in patients with lung cancers. XMT-1107 is a first-in-class anti-angiogenic conjugate that has completed a Phase 1 trial in patients with refractory, advanced solid tumors.  Both XMT-1001 and XMT-1107 are available for outlicensing on a worldwide basis.